Latest Market News

Matsa Resources has confirmed the unconditional status of its A$113 million option agreement with AngloGold Ashanti for the Lake Carey Gold Project, triggered by rising gold prices and strategic payments.

Leeuwin Metals has completed a significant phase of drilling at its Marda Gold Project, with assay results pending and plans underway for further exploration at a high-grade target.

PointsBet Holdings Limited updates shareholders on competing takeover bids, endorsing MIXI’s $1.20 cash offer while highlighting significant uncertainties and lower value in Betr Entertainment’s all-scrip proposal.

Invion Limited has announced a fully underwritten entitlement offer of Loyalty Options to raise capital for advancing its cancer clinical trials. The offer, led by Blue Ocean Equities and supported by CEO Prof Thian Chew, invites eligible shareholders to participate in a non-renounceable rights issue.

Prominence Energy has agreed to acquire a vast natural hydrogen and helium exploration portfolio on the Gawler Craton, backed by a $1.75 million capital raise and strategic board appointments.

The Calmer Co. International Limited has launched its Taki Mai kava tinctures on Amazon USA, marking a strategic expansion into a rapidly growing wellness segment. This move aims to capitalize on the booming US tincture market and strengthen the company’s foothold in natural relaxation products.

Trigg Minerals advances its Antimony Canyon Project with near-term pilot extraction plans and a strategic land expansion linking new mineralised zones in Utah, positioning itself to address critical US antimony supply needs.

Finder Energy has fast-tracked the development of its Kuda Tasi and Jahal oil fields in Timor-Leste through a strategic alliance with SLB, targeting initial production of up to 40,000 barrels per day. The company’s diversified portfolio and tight capital structure position it for multiple catalysts in the second half of 2025.

Jayride Group launches a new B2B SaaS platform aimed at transforming ground transportation with integrated payments, fleet management, and AI tools, promising higher margins and scalable growth.

Tryptamine Therapeutics has secured ethics approval to begin a pioneering clinical trial of TRP-8803, an IV-infused psilocin treatment, targeting adult patients with Binge Eating Disorder. The trial aims to evaluate safety and efficacy, with initial results expected by the end of 2025.

Noble Helium Limited has responded to ASX inquiries about recent unusual trading activity, attributing it to ongoing convertible note amendment negotiations but denying undisclosed information influenced the market.

Noble Helium has amended its convertible note terms with Obsidian Global, postponing share conversions until refinancing or September 2025, while issuing new shares and options as part of a strategic turnaround.